Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis
暂无分享,去创建一个
W. Nelson | Iman Mohammadi | P. Feuerstadt | C. Teigland | J. Dreyfus | A. Amin | D. Dahdal | Anny C Wong
[1] W. Nelson,et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis , 2021, Journal of managed care & specialty pharmacy.
[2] W. Nelson,et al. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis , 2021, SAGE open medicine.
[3] D. Gerding,et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. , 2020, The New England journal of medicine.
[4] W. Nelson,et al. Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis , 2020, Journal of medical economics.
[5] H. Tilg,et al. Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics , 2019, Annals of Internal Medicine.
[6] H. Nair,et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis , 2018, Journal of global health.
[7] R. Lynfield,et al. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals , 2018, The New England journal of medicine.
[8] L. Epstein,et al. Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Susan Gruber,et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.
[10] C. Brensinger,et al. Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States , 2017, Annals of Internal Medicine.
[11] M. Salavert,et al. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort , 2017, European Journal of Clinical Microbiology & Infectious Diseases.
[12] S. Allen,et al. National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals , 2016, BMC Infectious Diseases.
[13] A. Ananthakrishnan,et al. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection , 2016, Infection Control & Hospital Epidemiology.
[14] M. Salavert,et al. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[15] K. Garey,et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. , 2016, The Journal of hospital infection.
[16] E. Dubberke,et al. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach , 2016, BMC Infectious Diseases.
[17] Ed J. Kuijper,et al. Clostridium difficile infection , 2016, Nature Reviews Disease Primers.
[18] V. Vullo,et al. Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection , 2015, Antimicrobial Agents and Chemotherapy.
[19] K. Langa,et al. Hospitalization Type and Subsequent Severe Sepsis. , 2015, American journal of respiratory and critical care medicine.
[20] D. Leffler,et al. Clostridium difficile infection. , 2015, The New England journal of medicine.
[21] M. Olsen,et al. The morbidity, mortality, and costs associated with Clostridium difficile infection. , 2015, Infectious disease clinics of North America.
[22] C. Donskey,et al. Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis , 2015, Infection Control & Hospital Epidemiology.
[23] K. Garey,et al. Healthcare Resource Utilization for Recurrent Clostridium difficile Infection in a Large University Hospital in Houston, Texas , 2014, PloS one.
[24] Christine Leong,et al. Treatment Strategies for Recurrent Clostridium difficile Infection. , 2013, The Canadian journal of hospital pharmacy.
[25] David M Aronoff,et al. Epidemiology of Clostridium difficile Infection , 2013, Journal of pharmacy practice.
[26] Joshua A. Doherty,et al. Clostridium difficile Infection: A Multicenter Study of Epidemiology and Outcomes in Mechanically Ventilated Patients , 2013, Critical care medicine.
[27] S. Lowry,et al. Impact of infectious complications after elective surgery on hospital readmission and late deaths in the U.S. Medicare population. , 2012, Surgical infections.
[28] Margaret A. Olsen,et al. Burden of Clostridium difficile on the Healthcare System , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] Derrick W. Crook,et al. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] I. Brukner,et al. Host and pathogen factors for Clostridium difficile infection and colonization. , 2011, The New England journal of medicine.
[31] Stuart Johnson. Recurrent Clostridium difficile infection: causality and therapeutic approaches. , 2009, International journal of antimicrobial agents.
[32] K. Garey,et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.
[33] C. Manthous,et al. Clostridium difficile causing sepsis and an acute abdomen in critically ill patients. , 1995, Critical care medicine.
[34] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.